Why BioMarin FDA Panel is Positive for Sarepta (SRPT) - Oppenheimer

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/23/2026

1. USO
2. META
3. NVDA
4. SPY
5. MSFT
6. DCOY
7. RCL
8. ONON
9. VRTX
10. VKTX

Go back to Why BioMarin FDA Panel is Positive for Sarepta (SRPT) - Oppenheimer

Needham & Company Remains Confident in Sarepta Therapeutic (SRPT) Approval

November 25, 2015 12:09 PM EST

Needham & Company analyst Chad Messer reiterated a Buy rating and $55 price target on Sarepta Therapeutic (NASDAQ: SRPT) saying they remain confident in Eteplirsen approval following Drisapersen's AdCom.

Messer commented, "As expected, most of the discussion yesterday was around inconsistencies in the drisapersen... More

Sarepta (SRPT) PT Raised at Jefferies as BioMarin AdCom Viewed as a Positive But Remains Cautious

November 25, 2015 7:27 AM EST

Jefferies analyst Gena Wang views the negative AdCom outcome for BMRN's drisapersen as a positive for Sarepta Therapeutic (NASDAQ: SRPT), although questions remain. As such the firm raised its price target to $38.00 (from $28.00) but maintained a Hold rating.

Wang commented, "We view negative... More

Sarepta Therapeutics (SRPT) on Watch as BioMarin's (BMRN) Kyndrisa Adcom Set to Kickoff

November 24, 2015 7:46 AM EST

Sarepta Therapeutics (NASDAQ: SRPT) was on watch Tuesday morning ahead of competitor BioMarin's (Nasdaq: BMRN) Kyndrisa FDA committee review. The advisory meeting runs from 8:00 a.m. to 5:30 p.m. EST.

... More

FDA Briefing Docs Offer Positives and Negatives for Sarepta (SRPT) - Baird

November 23, 2015 6:55 AM EST

Baird analyst, Brian Skorney, published a note this morning highlighting his interpretation of the FDA Briefing Documents on BioMarin's (NASDAQ: BMRN) drisapersen filed Friday. He still believes that Sarepta (NASDAQ: SRPT) has only a 35% chance of getting approval for eteplirsen... More